Schwan: Roche to pursue 'targeted acquisitions'

Roche isn't pursuing any large deals, especially ones the size of Abbott Labs' ($ABT) recently announced overhaul, CEO Severin Schwan (photo) said in an interview. "We are not interested in mega-mergers. We are interested in very targeted acquisitions which complement our technologies and portfolios," he explained. News

Suggested Articles

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.